Application of value framework to phase iii trials of immune checkpoint inhibitors in esophageal and gastric cancer

HIGHLIGHTS

• who: The Oncologist and colleagues from the Knight Cancer Institute, Division of Hematology and Oncology, Oregon Health and Science University, Portland, OR, USA Department of Medicine, Oregon Health and Science University, Portland, OR, USA have published the research work: Application of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric Cancer, in the Journal: (JOURNAL)
• what: The authors aim to assess key subgroups using ASCO Net Health Benefit Score (NHBS) and ESMO Magnitude of Clinical Benefit Scale (MCBS). Regardless of statistical significance, the authors aimed to estimate the magnitude of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.